A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.
D000328:Adult; D023181:Antimicrobial Cationic Peptides; D002180:Candidiasis, Oral / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects / Q000382:microbiology / Q000528:radiation effects; D009325:Nausea / Q000139:chemically induced; D009910:Oral Hygiene; D010455:Peptides; D011506:Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000517:prevention & control*; D013280:Stomatitis / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*
D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D011506:Proteins; C119872:antimicrobial peptide IB-367